Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBIT Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBIT Margin for 17 consecutive years, with 2.72% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 1580.0% to 2.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 46.96%, a 3222.0% decrease, with the full-year FY2025 number at 46.96%, down 3222.0% from a year prior.
  • EBIT Margin was 2.72% for Q4 2025 at Myriad Genetics, up from 11.33% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2.72% in Q4 2025 to a low of 154.48% in Q2 2025.
  • A 5-year average of 28.82% and a median of 17.89% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: skyrocketed 6230bps in 2021, then plummeted -13722bps in 2025.
  • Myriad Genetics' EBIT Margin stood at 26.8% in 2021, then fell by -10bps to 29.36% in 2022, then surged by 46bps to 15.97% in 2023, then fell by -16bps to 18.52% in 2024, then surged by 85bps to 2.72% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBIT Margin are 2.72% (Q4 2025), 11.33% (Q3 2025), and 154.48% (Q2 2025).